​

BriaCell Therapeutics Stock (NASDAQ:BCTX)

FinancialsChart
BriaCell Therapeutics by TradingView

Previous Close

$2.11

52W Range

$0.35 - $9.82

50D Avg

$3.24

200D Avg

$2.43

Market Cap

$14.03M

Avg Vol (3M)

$1.79M

Beta

1.72

Div Yield

-

BCTX Company Profile

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

16

IPO Date

Mar 14, 2012

Website

BCTX Performance

BCTX Financial Summary

Jul 24Jul 23Jul 22
Revenue---
Operating Income$-4.79M$-23.27M$-15.29M
Net Income$-4.79M$-20.30M$-11.58M
EBITDA$-4.79M$-22.37M$-11.50M
Basic EPS$-0.29$-1.30$-0.75
Diluted EPS$-0.29$-1.30$-0.75

Fiscal year ends in Jul 24 | Currency in USD

Peer Comparison

TickerCompany
ALZNAlzamend Neuro, Inc.
MREOMereo BioPharma Group plc
PDSBPDS Biotechnology Corporation
XFORX4 Pharmaceuticals, Inc.
VRPXVirpax Pharmaceuticals, Inc.
DATSDatChat, Inc.
CNTXContext Therapeutics Inc.